J3247 Injection secukinumab intrav 1mg
Also known as: secukinumab, Cosentyx, interleukin-17 inhibitor
Secukinumab intravenous 1 milligram injection is a monoclonal antibody targeting interleukin-17 used for moderate to severe psoriasis, psoriatic arthritis, and ankylosing spondylitis.
In Plain Language
autoimmune disease injection; psoriasis/arthritis treatment
Clinical Context
Indicated for moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Blocks interleukin-17 signaling. Intravenous formulation for intensive treatment initiation.
RVU Information
CPT J3247 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J3247?
CPT J3247 (Injection secukinumab intrav 1mg) is a J Codes (Drugs) code. Secukinumab intravenous 1 milligram injection is a monoclonal antibody targeting interleukin-17 used for moderate to severe psoriasis, psoriatic arthritis, and ankylosing spondylitis.
How is J3247 administered?
CPT J3247 is administered by a healthcare provider, typically via injection or infusion. Indicated for moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Blocks interleukin-17 signaling. Intravenous formulation for intensive treatment initiation. It is used by Dermatology, Rheumatology, Internal Medicine.
When is CPT J3247 used?
Indicated for moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Blocks interleukin-17 signaling. Intravenous formulation for intensive treatment initiation.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.